ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0084

Prevalence, Length of Stay, and Hospitalization of AKI in Patients with and Without Sjogren Syndrome

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Ghandour, Mohamedanwar M., Wayne State University School of Medicine, Detroit, Michigan, United States
  • Osman Malik, Yahya M., Wayne State University School of Medicine, Detroit, Michigan, United States
Background

Acute Kidney Injury (AKI) has emerged as a significant cause of morbidity and mortality in patients with autoimmune diseases. However, this has not been examined in patients with Sjogren’s syndrome (SJS). To achieve this, we examined the prevalence, mortality, outcomes, Length of Stay (LOS), and hospital charges in patients with AKI with SJS compared to patients without SJS from a National Inpatient Sample database in the period 2010-2013.

Methods

Data retrieved from the National Inpatient Sample (NIS) for adult patients admitted with a principal diagnosis of acute kidney injury between 2010 and 2013, using the respective ICD-9 codes. The study population divided into two groups, with and without Sjogren’s disease. Multivariate and linear regression analysis conducted to adjust for covariates.

Results

The study population represented 97,055 weighted patient discharges with acute kidney injury. Analysis revealed acute kidney injury patients with Sjogren’s compared to patients without Sjogren’s had statistically significant lower hyperkalemia rates (adjusted Odds ratio (OR)0.65, CI 0.46 to 0.92; p =0.017). There was no statistically significant difference in mortality, length of stay, hospital charges, and other outcomes. Moreover, The charges of hospitalization and length of stay were found to be statistically insignificant by the adjusted linear regression model. In addition, nearly three quarters of patients had Medicare, followed by privately insured patients with the least number being on Medicaid. More than half of the population have received their treatment in a tertiary center hospital.Charlson’s index reported more than two-thirds of study subjects to have two or more co-morbidities.

Conclusion

At present, our study is unique as it has examined the prevalence, mortality, and outcomes of Sjogren’s in patients with acute kidney injury. Patients with Sjogren’s had significantly lower hyperkalemia during the hospitalization.Further research is needed to identify the underlying protective mechanisms associated with Sjogren’s that resulted in lower hyperkalemia.